Equities Analysts Offer Predictions for ARWR FY2025 Earnings

Key Points

• Cantor Fitzgerald has revised its earnings estimates for Arrowhead Pharmaceuticals, lowering the FY2025 EPS prediction from ($0.54) to ($0.94), while the consensus for the current full-year earnings is ($2.42) per share.
• Arrowhead Pharmaceuticals recently reported a quarterly earnings miss with an EPS of ($1.26), falling short of the consensus estimate by $0.32, along with revenue also below expectations at $27.77 million.
• Despite the earnings downgrade, two previous analysts' ratings maintain a "Strong Buy," and the company has a current consensus rating of "Buy" with a target price of $43.14.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Equities researchers at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for Arrowhead Pharmaceuticals in a note issued to investors on Wednesday, September 10th. Cantor Fitzgerald analyst P. Agrawal now forecasts that the biotechnology company will earn ($0.94) per share for the year, down from their prior estimate of ($0.54). The consensus estimate for Arrowhead Pharmaceuticals' current full-year earnings is ($2.42) per share. Cantor Fitzgerald also issued estimates for Arrowhead Pharmaceuticals' FY2026 earnings at ($2.24) EPS.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The firm had revenue of $27.77 million during the quarter, compared to analyst estimates of $29.01 million. During the same quarter in the previous year, the business posted ($1.38) earnings per share.

Several other brokerages have also commented on ARWR. Royal Bank Of Canada decreased their price objective on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating on the stock in a report on Friday, August 8th. Chardan Capital restated a "buy" rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 11th. TD Cowen upgraded Arrowhead Pharmaceuticals to a "strong-buy" rating in a research note on Monday, July 28th. HC Wainwright reissued a "buy" rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, September 2nd. Finally, B. Riley raised Arrowhead Pharmaceuticals to a "strong-buy" rating in a research note on Monday, August 11th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $43.14.

Arrowhead Pharmaceuticals Trading Up 1.2%

NASDAQ ARWR traded up $0.35 during trading hours on Friday, reaching $29.77. The company had a trading volume of 830,007 shares, compared to its average volume of 2,040,965. The stock has a 50-day moving average of $20.47 and a 200 day moving average of $16.68. Arrowhead Pharmaceuticals has a 1-year low of $9.57 and a 1-year high of $31.13. The company has a current ratio of 4.87, a quick ratio of 4.87 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of $4.12 billion, a P/E ratio of -23.24 and a beta of 1.00.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Oak Ridge Investments LLC increased its stake in Arrowhead Pharmaceuticals by 2.5% in the first quarter. Oak Ridge Investments LLC now owns 33,734 shares of the biotechnology company's stock valued at $430,000 after purchasing an additional 823 shares during the period. Resona Asset Management Co. Ltd. increased its position in Arrowhead Pharmaceuticals by 8.7% in the 2nd quarter. Resona Asset Management Co. Ltd. now owns 11,218 shares of the biotechnology company's stock valued at $180,000 after acquiring an additional 900 shares during the period. Empowered Funds LLC increased its position in Arrowhead Pharmaceuticals by 6.9% in the 1st quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company's stock valued at $194,000 after acquiring an additional 979 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in Arrowhead Pharmaceuticals by 9.0% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 14,476 shares of the biotechnology company's stock valued at $184,000 after acquiring an additional 1,195 shares during the period. Finally, KLP Kapitalforvaltning AS increased its holdings in shares of Arrowhead Pharmaceuticals by 5.2% in the second quarter. KLP Kapitalforvaltning AS now owns 24,300 shares of the biotechnology company's stock valued at $384,000 after purchasing an additional 1,200 shares during the period. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Arrowhead Pharmaceuticals

In other news, insider James C. Hamilton sold 15,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Friday, September 12th. The shares were sold at an average price of $30.00, for a total value of $450,000.00. Following the transaction, the insider directly owned 232,122 shares of the company's stock, valued at $6,963,660. The trade was a 6.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Over the last 90 days, insiders have sold 40,000 shares of company stock valued at $1,025,000. Insiders own 4.30% of the company's stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.